NYPRG 101
Alternative Names: BOL-148; NYPRG-101Latest Information Update: 02 Sep 2026
At a glance
- Originator Ceruvia Lifesciences
- Class Analgesics; Antidepressants; Antimigraines; Antipsychotics; Drug withdrawal therapies; Ergolines; Ergot alkaloids; Neuropsychotherapeutics; Small molecules
- Mechanism of Action Serotonin 5-HT2A receptor agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Alcoholism; Cluster headache; Migraine; Opioid-related disorders
Most Recent Events
- 27 Aug 2026 Ceruvia Lifesciences has patents pending for NYPRG 101 in the USA
- 27 Aug 2026 Ceruvia Lifesciences receives patent allowance for NYPRG 101 in the USA
- 03 Aug 2026 Ceruvia Lifesciences announces intention to submit Clinical Trial Application (CTA) for Cluster headache in Germany in September 2026